Overview of Lezine

Property	Description
Active ingredient	Levocetirizine dihydrochloride
Form	Film-coated tablets, oral solution
Pharmacological class	Antihistamine (H1-receptor antagonist)
General purpose	Symptomatic relief of allergy
Origin	Synthetic, R-enantiomer derivative

What Type of Medicine is Lezine and What is its Composition?

Lezine is a synthetic medicinal product whose active ingredient is Levocetirizine dihydrochloride, and it is fundamentally classified within the antihistamine pharmacological group. It functions specifically as a second-generation Histamine H1-receptor antagonist, a classification that underscores its high selectivity for peripheral receptors. The composition of Lezine centers on this single, potent compound, which is chemically known to be the active R-enantiomer derivative of the older antihistamine, Cetirizine. This specific molecular structure is clinically recognized for providing effective symptomatic relief while minimizing the central nervous system effects associated with earlier compounds.

What Forms Does Lezine Come in and What is its General Purpose?

Lezine is formulated for the oral route of administration and is primarily supplied in two high-level pharmaceutical preparations: film-coated tablets and an oral solution. The availability of the oral solution distinguishes it, offering an alternative for patient groups, such as children or adults with swallowing difficulties, ensuring ease of administration. The general purpose of the Levocetirizine dihydrochloride substance is to provide effective antiallergic action by directly blocking the effects of histamine. Pharmacological studies confirmed that Levocetirizine demonstrates strong H1 receptor binding affinity. By acting as an H1-blocker, the medicine works to interrupt the allergic cascade, offering symptomatic relief for the common discomforts of the immune reaction.

Regulatory References

NIH Drug Information

What side effects are possible with Lezine?

Possible Side Effects and Safety Information

The safety profile of Lezine (levocetirizine) is formally documented in government regulatory sources, classifying potential adverse reactions by both frequency and the affected System-Organ-Class (SOC).

Common and Uncommon Adverse Reactions

Adverse reactions reported in controlled clinical studies are categorized as follows:

Classification	Examples of Officially Listed Effects
Common (ge 1/100)	Somnolence (drowsiness), Fatigue, Dry Mouth, Headache, Nasopharyngitis (cold symptoms). In children, Pyrexia (fever) and Cough are also common.
Uncommon (ge 1/1,000)	Asthenia (weakness), Abdominal pain.

These effects primarily involve the Nervous System Disorders and Gastrointestinal Disorders SOCs.

Serious Reactions and Safety Constraints

Serious adverse reactions, reported mainly through post-marketing surveillance (Frequency Unknown), include instances of Anaphylaxis (severe allergic reaction), Urinary Retention, and neurological events like Convulsion (seizures) and Syncope (fainting).

Safety limitations and specific constraints documented in official labeling include:

Hypersensitivity: The medicine is contraindicated in patients with known hypersensitivity to the active substance or related piperazine derivatives.
Renal Impairment: It is contraindicated in patients with End-Stage Renal Disease (eGFR less than 15 mL/min). Dose adjustments are required for all other degrees of decreased renal function.
Interactions: Concurrent use with alcohol or other Central Nervous System (CNS) depressants may increase the risk of reduced mental alertness and impairment of performance.
Withdrawal Effect: New onset of Pruritus (severe itching) has been reported following the discontinuation of the medicine after long-term daily use.

Overdose and Emergency Response

The official regulatory description of Lezine (Levocetirizine dihydrochloride) overdose focuses on specific clinical manifestations and the required immediate emergency response.

Feature	Official Regulatory Statement
Documented Overdose Manifestations	Clinical manifestations primarily involve drowsiness and somnolence in adults. In the pediatric population, the initial presentation may include agitation and restlessness prior to the onset of drowsiness.
Physiological Systems Affected	High drug exposure can affect the Central Nervous System (e.g., stupor, confusion), Cardiovascular System (tachycardia), and Urinary System (urinary retention).
Population-Specific Overdose Notes	The risk of adverse reactions from high exposure is considered greater in patients with impaired renal function.
Emergency-Response Statements	In case of an overdose, the patient must get medical help or contact a Poison Control Center right away.

Should overdose occur, symptomatic and supportive treatment is the official regulatory approach. There is no known specific antidote for Levocetirizine dihydrochloride. Furthermore, the substance is not effectively removed by haemodialysis, an important consideration for clinical management. Medical professionals may consider gastric lavage following a documented short-term ingestion of the medicine.

The mandatory emergency-seeking conditions are established by the explicit labeling requirement to seek medical help immediately, emphasizing a management strategy centered on supportive care due to the documented absence of a specific antidote and the ineffectiveness of dialysis in removal.

Therapeutic Uses of Lezine

What Lezine Treats: Main Uses and Benefits

Lezine (Levocetirizine) is generally used for symptomatic relief across therapeutic domains where patient discomfort arises from allergic reactions. It is applied in contexts requiring short-term symptomatic support or the long-term management of persistent allergic conditions.

The medication is commonly used to help with conditions characterized by periods of heightened symptoms, including seasonal and perennial allergic rhinitis (SAR/PAR), and the uncomplicated skin manifestations of chronic idiopathic urticaria (CIU). Its use is relevant when supportive symptom management is appropriate for these conditions.

It supports patients during episodes of heightened discomfort by easing the overall symptom load and is used for managing symptoms that may become intense or disruptive, such as persistent sneezing, profuse runny nose, nasal itching, ocular pruritus, and the appearance of wheals.

“This therapeutic assistance may help patients cope more steadily with symptom fluctuations arising from environmental triggers or chronic conditions.”

Quick Fact: Relief for Persistent Itching

Lezine is commonly used to help manage the disruptive symptom of pruritus (skin itching) associated with chronic hives, symptoms that interfere with daily functioning.

Eligibility and Restrictions for Use

Who Can and Cannot Use Lezine?

The official regulatory profile for Lezine (Levocetirizine dihydrochloride) strictly defines eligibility based on a patient's known sensitivity and renal function status.

Absolute Contraindications

Lezine is contraindicated in patients with a known allergy or hypersensitivity to the medicine, any of its ingredients, or to the related parent compound, cetirizine.

Due to the medicine's primary renal elimination pathway, use is also mathbfprohibited in adults and adolescents with mathbfend-stage renal disease (creatinine clearance < 10 mL/min) or those mathbfundergoing hemodialysis. Crucially, the medicine is also mathbfcontraindicated in children aged 6 months to 11 years who have mathbfany degree of impaired renal function.

Approved Age Groups and Conditional Use

Lezine is approved for use in mathbfadults and adolescents 12 years and older, as well as mathbfchildren 6 months to 11 years (using appropriate liquid formulations for dose adaptation). Safety and efficacy have mathbfnot been established for use in infants under 6 months of age.

Adults with mild or moderate renal impairment may be eligible, but use is mathbfrestricted and requires mathbfindividualized monitoring. mathbfNo dose adjustment is needed for patients with solely mathbfhepatic impairment. Additionally, mathbfcaution is advised for use in patients with predisposing factors for mathbfurinary retention.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Lezine (Levocetirizine) is structured around managing effects on the central nervous system and pharmacokinetic changes related to elimination, as documented in official regulatory sources.

Official Interaction Statements

Interaction Type	Interacting Substance/Condition	Regulatory Statement
Pharmacodynamic	Alcohol or CNS Depressants (e.g., sedatives, tranquilizers)	Concurrent use may cause additive impairment of central nervous system performance and reductions in alertness.
Pharmacokinetic	Ritonavir	Co-administration is documented to increase the plasma exposure (AUC and half-life) and decrease the clearance of the parent drug, Cetirizine.
Absorption	Food	Food does not affect the extent of drug exposure (AUC), but the rate of absorption is decreased. Lezine may be administered with or without food.
Population-Specific	Hepatic Impairment	No dosage adjustment is required in patients with hepatic impairment, as Levocetirizine metabolism is minimal.

Interaction-Related Restrictions

Contraindicated Combinations

The use of Lezine is formally contraindicated in certain populations due to the risk of reduced clearance and subsequent adverse reactions:

Patients with End-Stage Renal Disease (Creatinine Clearance <10 mL/min) or those undergoing hemodialysis.
Pediatric patients (6 months to 11 years of age) with any degree of impaired renal function.

Tested Non-Interactions

Official studies have documented no clinically relevant adverse interactions when Levocetirizine was co-administered with Antipyrine, Azithromycin, Cimetidine, Erythromycin, Ketoconazole, Theophylline, or Pseudoephedrine.

Mechanism of Action

Targeting the Histamine H1 Receptor

Lezine's primary action involves the active ingredient levocetirizine functioning as a selective antagonist of the peripheral Histamine H1 receptor. This mechanism is characterized by the drug binding to the receptor site and thereby physically preventing the naturally occurring signaling molecule, histamine, from attaching. This receptor blockade inhibits the initiation of the histamine-driven cascade at the molecular level.

Modulating Downstream Physiological Responses

Antagonism of the H1 receptor leads to the modulation of two key physiological consequences. The first is an influence on vascular permeability, as the drug limits the histamine-induced increase in the ability of small blood vessels (capillaries) to extravasate fluid and proteins. This results in a decrease in extravasated fluid volume, which affects the localized fluid balance of the tissues. The second consequence is the inhibition of stimulation of peripheral sensory nerves, preventing histamine from triggering associated signal transduction events within the nervous system.

Dosage and Administration Information

Lezine (levocetirizine dihydrochloride) is administered exclusively via the oral route using two primary pharmaceutical forms: a 5 mg film-coated tablet and an oral solution. The standard regimen requires the medicine to be taken once daily in a single intake. Dosing is typically scheduled for the evening and may be administered with or without food.

The standard daily dose for adults and adolescents (12 years of age) is 5 mg. The 5 mg tablet is scored and can be divided to provide a 2.5 mg dose when necessary, although the maximum adult dose is 5 mg per day. Specific lower daily doses are required for pediatric populations: 2.5 mg for children 6 to 11 years, and 1.25 mg for children 6 months to 5 years, typically managed with the oral solution. The tablet form is generally not used for children under 6 years due to the inability to achieve the precise required dose.

Administration duration follows two distinct patterns based on the condition's nature. For conditions that appear intermittently, the medicine may be used on an as-needed basis (intermittent use), stopping when symptoms subside and restarting if they reappear. For persistent conditions, continuous therapy is utilized, with clinical experience supporting use for at least six months.

A critical administration protocol involves mandatory dosage and frequency adjustment for patients with renal impairment. Doses are individualized, requiring reduced frequency (e.g., 2.5 mg every two days for moderate impairment). The medicine is not used in cases of End-Stage Renal Disease (CrCl < 10 mL/min). Isolated hepatic impairment does not require a dose change.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lezine

Evidence for Use in Seasonal and Perennial Allergic Rhinitis

The primary research base for Lezine (levocetirizine) involves Randomized Controlled Trials (RCTs), many of which are double-blind and compare the medicine to a placebo. Systematic reviews and large studies consolidate findings for allergic rhinitis, a condition characterized by fluctuating or episodic manifestations. These studies primarily focused on outcomes related to physical discomfort and changes in day-to-day functioning. Studies conducted in these short-term and intermediate-term research scenarios report measurements across the symptom scoring scales. Levocetirizine was studied for both seasonal allergic rhinitis, where symptoms are temporary or episodic, and perennial allergic rhinitis, where research explores symptom patterns over longer periods, often up to six months.

Evidence for Use in Chronic Idiopathic Urticaria (Hives)

The research examining Lezine for chronic idiopathic urticaria (hives) also largely relies on Randomized Controlled Trials (RCTs) and systematic evaluations. This condition is marked by functional limitations and involves periods of heightened symptoms, primarily persistent itching (pruritus) and the appearance of raised patches of skin (wheals). The studies explored outcomes related to physical discomfort, specifically tracking changes in the frequency and intensity of itching and the size of the wheals over defined time intervals. Trial findings describe group patterns of how patient-reported outcomes describing perceived discomfort evolved during the study period, typically over several weeks.

Duration of Evidence: Long-term Studies and Follow-up

The major clinical trials for Levocetirizine for both allergic rhinitis and chronic hives typically involved follow-up durations ranging from four to six weeks, extending up to six months in perennial rhinitis studies. Research exploring short-term symptom changes is extensive. Evidence describing how symptoms are measured and evolve is available for these defined intervals. However, long-term effects are not fully established, particularly concerning continuous use beyond six months for either indication. There is limited information for long-term outcomes, and research has not been extensive in examining outcomes describing persistent stability or symptom recurrence.

Evidence in Special Populations

Research has evaluated Levocetirizine in multiple population groups, including adults, adolescents, and children aged six years and older. Conversely, data for certain groups remain insufficient. For children under the age of six years, evidence often relies on studies monitoring physiological strain or stress and pharmacokinetic modeling, rather than large-scale, dedicated symptom-based RCTs. The research describes group patterns for patients with complex coexisting medical conditions, as these groups were often excluded from the core clinical trials.

Key Studies & References XYZAL (levocetirizine dihydrochloride) tablet, film coated; solution (DailyMed/NIH)

Frequently Asked Questions (FAQ)

Common questions about Lezine (FAQ)

Q: What is the difference between a first-generation and a second-generation antihistamine like Lezine?

Lezine is classified as a second-generation antihistamine, meaning it was developed to be more selective for the peripheral Histamine H1 receptors in the body. This selectivity is why the drug is associated with minimized effects on the central nervous system (CNS), such as the increased drowsiness and cognitive impairment often seen with older first-generation antihistamines.

Q: Is Lezine considered a preventative medicine or a treatment for active symptoms?

Official documents describe the medicine's use for symptomatic relief of allergic conditions. For people with persistent conditions, it may be used as continuous maintenance therapy. For those with episodic symptoms, it is used intermittently (as needed) to treat symptoms once they appear.

Q: Can Lezine cause a dry mouth or change in vision?

Official safety data lists dry mouth as a commonly reported side effect. Adverse events related to vision, such as blurred vision and accommodation disorder (difficulty focusing), have also been reported, but they are categorized as rare or very rare.

Q: Is it possible to experience dizziness while taking Lezine?

Regulatory documents list dizziness as a common adverse reaction to Lezine, meaning it has been reported in 1% to 10% of patients in clinical trials.

Q: Can Lezine be taken at the same time as cold and flu relief products or common pain relievers?

No clinically relevant adverse interaction is reported with common over-the-counter pain relievers like ibuprofen or paracetamol, or the decongestant pseudoephedrine. The official information advises caution when combining Lezine with any medicine that causes drowsiness, which may be an ingredient in some cold and flu products.

Q: Does Lezine interact with herbal supplements or vitamins?

No interaction is reported with common vitamins like Vitamin C. Due to the lack of extensive regulatory research covering all available herbal supplements, official documents recommend seeking guidance from a healthcare provider regarding supplement use.

Q: How quickly does Lezine begin to work after taking a dose?

Pharmacokinetic data shows that maximum plasma concentrations are typically reached within one hour, and symptom improvement has been reported to occur as early as two hours after administration. The medicine is classified as rapidly absorbed.

Q: How long does the effect of a single dose of Lezine typically last?

The therapeutic effect of Lezine is generally described as lasting 24 hours, which supports its once-daily dosing regimen. The plasma half-life in adults is approximately 7.9 hours.

Q: How is the use of Lezine described for pregnant individuals in regulatory information?

Official regulatory information classifies Lezine as Pregnancy Category B. The official classification indicates that the medicine is typically used during pregnancy only when the potential benefit is determined to justify the potential risk.

Q: What are the official guidelines regarding the use of Lezine while breastfeeding?

Based on limited data, the substance is generally not prohibited for use while breastfeeding. The official information notes that due to the potential for drowsiness in the infant, use during breastfeeding requires careful consideration.

Q: Are there specific warnings for older adults (seniors) using Lezine?

Regulatory documents recommend a specific dose adjustment for older patients who are also experiencing moderate to severe renal impairment (kidney function issues), due to the higher likelihood of age-related decreases in kidney function.

Q: Does Lezine have a safety classification regarding the ability to drive or operate machinery?

The official label includes a warning that individuals should not drive or operate machinery until they are certain how the medicine affects their alertness, due to the risk of drowsiness and reduced mental alertness.

Q: Is Lezine available over-the-counter or is it prescription-only in most regions?

Official information indicates that Levocetirizine is available as both an over-the-counter (OTC) medicine and a prescription medicine. Its specific availability status depends on the product formulation and the region.

Q: Does Lezine help with a blocked nose or is it mainly for a runny nose and itching?

Studies conducted for persistent allergic rhinitis report that Levocetirizine provided symptomatic relief for nasal congestion. This effect is in addition to treating the symptoms of allergic reactions, such as a runny nose and itching.

Q: Is Lezine known to have an effect on a person's mood or anxiety levels?

Post-marketing surveillance has included reports of psychiatric adverse reactions, such as mood changes, anxiety, agitation, and aggressive behavior. These reports are carefully monitored by regulatory bodies.

Q: Are there any reported instances of Lezine causing a temporary metallic taste?

Adverse reactions reported in official sources include a change in or loss of taste (dysgeusia). This category of side effects covers the concern about experiencing an unusual or metallic taste.

Q: What special precautions, if any, are listed for individuals with glaucoma using Lezine?

Lezine, similar to other antihistamines, carries a precaution for use in patients with predisposing factors for a condition called angle-closure glaucoma. Individuals with glaucoma should seek guidance from their ophthalmologist or healthcare provider before use.

Q: Where is the official patient information leaflet (PIL) for Lezine usually published?

The official Patient Information Leaflet (PIL) or Medication Guide is typically provided by the dispensing pharmacy. This information is also often published online by regulatory bodies (like DailyMed) and trusted public health resources.

Q: Does Lezine contain common allergens like lactose, gluten, or certain dyes?

The film-coated tablet formulation of Lezine lists Lactose Monohydrate as an inactive ingredient. Individuals with known sensitivities or allergies are encouraged to verify the specific inactive ingredients list for their particular formulation.

How should Lezine be stored and disposed of?

Storage and Handling

The official storage requirements for Lezine (levocetirizine dihydrochloride) are defined to maintain product stability and safety. The tablets must be stored at controlled room temperature, typically between 20°C and 25°C (68°F and 77°F). All forms of the medicine must be protected from heat, moisture, and direct light.

Stability and Container Rules

Lezine must be kept in its original, closed container. The oral solution has a specific in-use stability period and must be discarded 3 months after first opening. A mandatory instruction is to keep the medicine out of the sight and reach of children.

Disposal

Expired or unused Lezine should not be disposed of via wastewater or thrown directly into household trash, as specified in regulatory guidelines. Disposal must occur in accordance with local requirements, often involving an approved pharmacy or drug take-back program.

Lezine